Yeni Stratejiler Antiviral İlaç Direncine Alternatif Olabilir mi?

Yıl 2018, Cilt: 29 Sayı: 1, 59 - 62, 30.04.2018

Zafer Yazıcı

Öz

Viral ajanlar, insanlarda ve hayvanlarda hayatı tehdit eden kronik enfeksiyonlara, ölümlere ve ekonomik kayıplara neden olmaya devam etmektedir. Günümüzde insan, hayvan ve zoonotik virus enfeksiyonlarının tedavisi için sınırlı sayıda antiviral ilaç mevcuttur. Oluşan antiviral ilaç direnci bu viruslar ile enfekte hastaların tedavisi için engel teşkil etmektedir. Viral enfeksiyonlar ile mücadele için yeni stratejiler ya da taktikler geliştirerek oluşan antiviral ilaç direncinin önlenmesine ihtiyaç vardır. Günümüzde fidelite varyantlarının ve letal mutagenezin ilaç direncinin önlenmesi için etkili stratejiler olduğu düşünülmektedir. Bu derleme viral enfeksiyonlar ile mücadele amacı ile geliştirilmesi denenen yeni stratejileri ve antiviral mekanizmaları özetlemektedir.

Anahtar Kelimeler

Virus, Antiviral ilaçlar, Letal mutagenez, Fidelite varyantları

Can New Strategies Be An Alternative To Antiviral Drug Resistance?

Öz

Viral agents have been continuing to cause life threatening chronic infections, deaths and economic losses in humans and animals. Recently a limited number of antiviral drug is available to treat human, animal and zoonotic virus infections. The emergence of resistance to these antivirals has created an obstacle for the treatment of patients who infected with viruses. To struggle with viral infections, there is need to prevent the emergence of antiviral drug resistance by developing the new strategies or tactics. Recently fidelity variants and lethal mutagenesis is considered to be an effective strategy for the prevention of drug resistance. This review summarises the new strategies and antiviral mechanisms being tried to develop in order to fight viral infections.

Anahtar Kelimeler

Virus, Antiviral drugs, Lethal mutagenesis, Fidelity variants

Kaynakça

• Arisa A, Thorne L, Goodfellow I (2014). Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife, 3: e03679, doi:10.7554/elife.03679. Baskin H, Yazici Z, Baskin Y, Olgun N, Ozkul A, Bahar HI (2005). Effects of non toxic doses of acyclovir on nitric oxide and cellular death responses in herpesviruses type 1 and 2 infected HEp-2 cells. New Microbiol, 28, 205-213. Belshaw R, Gardner A, Rambaut A, Pybus OG (2008). Pacing a small cage: mutation and RNA viruses. Trends Ecol Evol, 23, 188-193. Bull JJ, SanjuanR, Wilke CO (2007). Theory of Lethal Mutagenesis for Viruses. J Virol, 81, 2930–2939. Campagnola G, McDonald S, Beaucourt S, Vignuzzi M, Peersen OB (2014). Structure-function relationships underlying the replication fidelity of viral RNA-dependent RNA polymerase. J Virol, 89, 275-286. Costa L, Faustino MA, Neves MG, Cunha A, Almeida A (2012). Photodynamic inactivation of mammalian viruses and bacteriophages. Viruses, 4, 1034-1074. Dapp MJ, Clouser CL, Patterson S, Mansky LM (2009). 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol, 83, 11950-11958. Ferrer-Orta C, Sierra M, Agudo R, et al. (2010). Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin.J Virol, 84, 6188-6199. Graci JD, Cameron CE (2008). Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol, 3, 553-556. Grande-Pérez A, Sierra S, Castro MG, Domingo E, Lowenstein PR (2002). Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci, 99, 12938-12943. Igde M, Yazici Z (2012). Possible antiviral activity of montelukast against herpes simplex virus type-1 and human adenovirus in vitro. African J Microbiol Res, 6,197-202. Khatun A, Shabir N, Yoon K, Kim W (2015). Effects of ribavirin on the replication and genetic stability of porcine reproductive and respiratory syndrome virus BMC Vet Res, 11, 21, 1-15 doi: 10.1186/s12917-015-0330-z. Lazaro E (2011). RNA viruses: Control, mutagenesis and Extinction. eLS, doi 10.1002/980470015902.a0023276,2011. Lazaro E (2014). RNA virus evolution at variable error rate. Future Virol, 9,665-677. Loeb LA, Essigmann JM, Kazazi F, Zhang J, Rose KD, Mullins JI (1999). Lethal mutagenesis of HIV with nucleoside analogs. Proc Natl Acad Sci, 96, 1492-1497. Lou Z, Sun Y, Rao Z (2014). Current progress in antiviral strategies. Trends Pharmacol Sci, 35, 86-102. Mack R (1970). The great African cattle plague epidemic of the 1890’s.Trop Anim Health Prod, 2, 210-219. Martinez JP, Sasse F, Bronstrup M, Diez J, Meyershans A (2015). Antiviral drug discovery: broad spectrum drugs from nature. Nat Prod Rep, 32, 29-41. Meng T, Kwang J (2014). Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol ,88, 5803-5815. Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, Martín V (2011). Ribavirin ban be mutagenic for Arenaviruses. J Virol, 85,7246-7225. Mullins JI, Heath L, Hughes JP et al. (2011). Mutation of HIV-1 Genomes in a Clinical Population Treated with the Mutagenic Nucleoside KP1461. PLoS ONE 6(1): e15135. https://doi.org/10.1371/journal. pone. 0015135 Novella IS, Preloid JB, Taylor RT (2014). RNA replication errors and the evolution of virus pathogenicity and virulence. Curr Opin Virol, 9,143-147. Pauly MD, Lauring AS (2015). Effective lethal mutagenesis of influenza virus three nucleoside analogs. J Virol, 89, 3584-3597. Perales C, Martin V, Domingo E (2011). Lethal mutagenesis of viruses. Curr Opin Virol, 1, 419-422. Rozen-Gagnon K, Stapleford K, Mongelli V et al. (2014). Alphavirus Mutator Variants Present Host-Specific Defects and Attenuation in Mammalian and Insect Models’, PLoS Pathogens, 10: e1003877. Ruiz-Jarabo CM, Ly C, Domingo E, de la Torre JC (2003). Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology, 308, 37-47. Sierra S, Dávila M, Lowenstein PR, Domingo E (2010). Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol, 74, 8316-8323. Smith EC, Sexton NR, Denison MR (2014). Thinking outside the triangle replication fidelity of the largest RNA viruses. Ann Rev Virol,1, 111-132. Taubenberger JK, Morens DM (2006). 1918 influenza:The mother of all pandemics. Emerg Infect Dis, 12,15-22. WHO (2015). Ebola situation report May 13, http://apps.who.int/ebola /en/ebola-situation-reports Xie X, Wang H, Zeng J, Li C, Zhou G, Yang D (2014). Foot and mouth disease virus low-fidelity polymerase mutant polymerase mutants are attenuated. Arch Virol,159, 2641-2650. Zeng J, Wang H, Xie X et. (2014). Ribavirin-Resistant Variants of Foot-and-Mouth Disease Virus: the Effect of Restricted Quasispecies Diversity on Viral Virulence. J Virol,88, 4008-4020.